{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:19:37Z","timestamp":1771658377433,"version":"3.50.1"},"reference-count":99,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Non-ischemic dilated cardiomyopathy encompasses a wide spectrum of myocardial disorders, characterized by left ventricular dilatation with systolic impairment and increased risk of sudden cardiac death. In spite of all the therapeutic progress that has been made in recent years, dilated cardiomyopathy continues to be an important cause of cardiac transplant, being associated with an enormous cost burden for health care systems worldwide. Predicting the prognosis of patients with dilated cardiomyopathy is essential to individualize treatment. Late gadolinium enhancement-cardiac magnetic resonance imaging, microvolt T-wave alternans, and genetic testing have emerged as powerful tools in predicting sudden cardiac death occurrence and maximizing patient\u2019s selection. Despite all these new diagnostic modalities, additional tests to complement or replace current tools are required for better risk stratification. Therefore, biomarkers are an easy and important tool that can help to detect patients at risk of adverse cardiovascular events. Additionally, identifying potential biomarkers involved in dilated cardiomyopathy can provide us important information regarding the diagnostic, prognostic, risk stratification, and response to treatment for these patients. Many potential biomarkers have been studied in patients with dilated cardiomyopathy, but only a few have been adopted in current practice. Therefore, the aim of our review is to provide the clinicians with an update on the well-known and novel biomarkers that can be useful for risk stratification of patients with non-ischemic dilated cardiomyopathy.<\/jats:p>","DOI":"10.3390\/ijms22115688","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T21:56:44Z","timestamp":1622066204000},"page":"5688","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-ischemic Dilated Cardiomyopathy"],"prefix":"10.3390","volume":"22","author":[{"given":"Larisa","family":"Anghel","sequence":"first","affiliation":[{"name":"Internal Medicine Department, \u201dGrigore T. Popa\u201d University of Medicine and Pharmacy, 700503 Ia\u0219i, Romania"},{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I. M. Georgescu\u201d, 700503 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radu","family":"Sasc\u0103u","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, \u201dGrigore T. Popa\u201d University of Medicine and Pharmacy, 700503 Ia\u0219i, Romania"},{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I. M. Georgescu\u201d, 700503 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4053-4130","authenticated-orcid":false,"given":"Ioana M\u0103d\u0103lina","family":"Zota","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, \u201dGrigore T. Popa\u201d University of Medicine and Pharmacy, 700503 Ia\u0219i, Romania"},{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I. M. Georgescu\u201d, 700503 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6439-4561","authenticated-orcid":false,"given":"Cristian","family":"St\u0103tescu","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, \u201dGrigore T. Popa\u201d University of Medicine and Pharmacy, 700503 Ia\u0219i, Romania"},{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I. M. Georgescu\u201d, 700503 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jacc.2019.12.058","article-title":"Emerging techniques for risk stratification in nonischemic dilated cardiomyopathy: JACC review topic of the week","volume":"75","author":"Marrow","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classification of the cardiomyopathies: A position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"29","author":"Elliott","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/ejhf.1216","article-title":"Sex- and age- based differences in the natural history and outcome of dilated cardiomyopathy","volume":"20","author":"Halliday","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-020-01343-9","article-title":"Sudden cardiac death prediction in non-ischemic dilated cardiomyopathy: A multiparametric and dynamic approach","volume":"22","author":"Hammersley","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"70","author":"Yancy","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cjca.2019.11.009","article-title":"A novel risk stratification score for sudden cardiac death prediction in middle-aged, nonischemic dilated cardiomyopathy patients: The ESTIMATED score","volume":"36","author":"Li","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1161\/CIRCULATIONAHA.106.683110","article-title":"Benchmarks for the assessment of novel cardiovascular biomarkers","volume":"115","author":"Morrow","year":"2007","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMra0800239","article-title":"Biomarkers in heart failure","volume":"358","author":"Braunwald","year":"2008","journal-title":"N. Eng. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4236\/health.2018.103024","article-title":"Classification of new biomarkers of dilated cardiomyopathy based on pathogenesis\u2014An update","volume":"10","author":"Dookhun","year":"2018","journal-title":"Health"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1161\/01.CIR.0000159336.31613.31","article-title":"Inflammation and endothelial function: Direct vascular effects of human C-reactive protein on nitric oxide bioavailability","volume":"111","author":"Clapp","year":"2005","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/apc.APC_47_18","article-title":"Neutrophil-to-lymphocyte ratio used as prognostic factor marker for dilated cardiomyopathy in childhood and adolescence","volume":"12","author":"Silva","year":"2019","journal-title":"Ann. Pediatr. Card."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1755-7682-5-2","article-title":"Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population","volume":"5","author":"Imtiaz","year":"2012","journal-title":"Int. Arch. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1388-9842(02)00021-1","article-title":"C-Reactive Protein as a predictor of improvement and readmission in heart failure","volume":"4","year":"2002","journal-title":"Eur. J. Heart Fail."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ahj.2003.11.021","article-title":"Independent prognostic value of elevated high-sensitivity C-Reactive Protein in chronic heart failure","volume":"147","author":"Yin","year":"2004","journal-title":"Am. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.cardfail.2004.08.026","article-title":"Plasma C-reactive protein is an independent prognostic predictor in patients with dilated cardiomyopathy","volume":"10","author":"Chitose","year":"2004","journal-title":"J. Card. Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-019-1236-3","article-title":"Risk stratification for sudden cardiac death in non-ischaemic dilated cardiomyopathy","volume":"21","author":"Akhtar","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/01.CIR.0000153349.77489.CF","article-title":"Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure","volume":"111","author":"Katz","year":"2005","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2261-14-67","article-title":"Plasma NT pro-BNP, hs-CRP and big-ET levels at admission as prognostic markers of survival in hospitalized patients with dilated cardiomyopathy: A single-center cohort study","volume":"14","author":"Li","year":"2014","journal-title":"BMC Cardiovasc. Disord."},{"key":"ref_20","first-page":"49420","article-title":"Circulating biomarkers of dilated cardiomyopathy\u2014An analysis of new potential biomarkers","volume":"9","author":"Dookhun","year":"2017","journal-title":"Int. J. Curr. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e000298","DOI":"10.1136\/openhrt-2015-000298","article-title":"MRI and serum high-sensitivity C-reactive protein predict long-term mortality in non-ischaemic cardiomyopathy","volume":"2","author":"Sadahiro","year":"2015","journal-title":"Open Heart"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3109\/14017431.2014.932922","article-title":"Neutrophil\/lymphocyte ratio is related to the severity of idiopathic dilated cardiomyopathy","volume":"48","author":"Avci","year":"2014","journal-title":"Scand. Cardiovasc. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurjhf\/hfn039","article-title":"Inflammation in chronic heart failure: What is familiar, what is unfamiliar?","volume":"11","author":"Fu","year":"2009","journal-title":"Eur. J. Heart Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.amjcard.2010.09.039","article-title":"Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure","volume":"107","author":"Uthamalingam","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2015.02.008","article-title":"Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy","volume":"184","author":"Vergaro","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.amjcard.2016.09.019","article-title":"Meta-analysis of the usefulness of plasma galectin-3 to predict the risk of mortality in patients with heart failure and in the general population","volume":"119","author":"Imran","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/HPC.0000000000000171","article-title":"Myocardial fibrosis as a pathway of prediction of ventricular arrhythmias and sudden cardiac death in patients with nonischemic dilated cardiomyopathy","volume":"18","author":"Alderete","year":"2019","journal-title":"Crit. Pathw. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s10554-016-0958-1","article-title":"Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients","volume":"32","author":"Hu","year":"2016","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cardfail.2015.10.022","article-title":"Prognostic value of galectin-3 for adverse outcomes in chronic heart failure","volume":"22","author":"French","year":"2016","journal-title":"J. Card. Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e000750","DOI":"10.1136\/openhrt-2017-000750","article-title":"The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure","volume":"5","author":"Binas","year":"2018","journal-title":"Open Heart"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"E276","DOI":"10.1532\/hsf.2885","article-title":"Serum chemerin predicts the prognosis of patients with dilated cardiomyopathy","volume":"23","author":"Chen","year":"2020","journal-title":"Heart Surg. Forum"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3109\/10641963.2013.827697","article-title":"Chemerin is associated with inflammatory markers and metabolic syndrome phenotypes in hypertension patients","volume":"36","author":"Gu","year":"2014","journal-title":"Clin. Exp. Hypertens."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2015.05.018","article-title":"Circulating chemerin levels elevated in dilated cardiomyopathy patients with overt heart failure","volume":"448","author":"Zhang","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e012091","DOI":"10.1161\/JAHA.119.012091","article-title":"Serum chemerin as a novel prognostic indicator in chronic heart failure","volume":"8","author":"Zhou","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1536\/ihj.17-293","article-title":"Tumor necrosis factor-\u03b1 gene polymorphism (G-308A) and dilated cardiomyopathy","volume":"60","author":"Chen","year":"2019","journal-title":"Int. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e13386","DOI":"10.1097\/MD.0000000000013386","article-title":"Association between rs1800629 polymorphism in tumor necrosis factor-\u03b1 gene and dilated cardiomyopathy susceptibility: Evidence from case\u2013control studies","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/heart.89.1.14","article-title":"Therapeutic inhibition of tumour necrosis factor \u03b1 in patients with heart failure: Cooling an inflamed heart","volume":"89","author":"Henriksen","year":"2003","journal-title":"Heart"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lup\u00f3n, J., De Antonio, M., Vila, J., Pe\u00f1afiel, J., Gal\u00e1n, A., Zamora, E., Urrutia, A., and Bayes-Genis, A. (2014). Development of a novel heart failure risk tool: The Barcelona bio-heart failure risk calculator (BCN bio-HF calculator). PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085466"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Chmielewski, P., Michalak, E., Kowalik, I., Franaszczyk, M., Sobieszczanska-Malek, M., Truszkowska, G., Stepien-Wojno, M., Biernacka, E.K., Foss-Nieradko, B., and Lewandowski, M. (2020). Can circulating cardiac biomarkers be helpful in the assessment of LMNA mutation carriers?. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051443"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1751-7133.2009.00095.x","article-title":"Prognostic utility of right ventricular systolic functions assessed by tissue doppler imaging in dilated cardiomyopathy and its correlation with plasma NT-pro-BNP levels","volume":"15","author":"Tigen","year":"2009","journal-title":"Congest. Heart Fail."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11897-010-0005-9","article-title":"ST2: A novel remodelling biomarker in acute and chronic heart failure","volume":"7","author":"Shah","year":"2010","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jchf.2013.03.007","article-title":"Surfing the biomarker tsunami at JACC: Heart failure","volume":"1","author":"Januzzi","year":"2013","journal-title":"JACC Heart Fail."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1373\/clinchem.2011.165720","article-title":"Emerging biomarkers in heart failure","volume":"58","author":"Januzzi","year":"2012","journal-title":"Clin. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"26B","DOI":"10.1016\/j.amjcard.2015.01.037","article-title":"ST2 and prognosis in acutely decompensated heart failure: The International ST2 Consensus Panel","volume":"115","author":"Januzzi","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_45","first-page":"2048004020957840","article-title":"Galactin-3 and soluble ST2 as complementary tools to cardiac MRI for sudden cardiac death risk stratification in heart failure: A review","volume":"9","author":"Shah","year":"2020","journal-title":"JRSM Cardiovasc. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1016\/j.jacc.2009.07.041","article-title":"Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction","volume":"54","author":"Tornel","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijcard.2014.11.003","article-title":"Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure","volume":"179","author":"Broch","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.hjc.2017.03.006","article-title":"Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients","volume":"58","author":"Wojciechowska","year":"2017","journal-title":"Hell. J. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cjca.2019.02.016","article-title":"Association of soluble ST2 serum levels with outcomes in paediatric dilated cardiomyopathy","volume":"35","author":"You","year":"2019","journal-title":"Can. J. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/eurjhf\/hfp072","article-title":"Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure","volume":"11","author":"Tsutamoto","year":"2009","journal-title":"Eur. J. Heart Fail."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1253\/circj.CJ-10-0837","article-title":"Prognostic role of high-sensitivity cardiac troponin T in patients with nonischemic dilated cardiomyopathy","volume":"75","author":"Kawahara","year":"2011","journal-title":"Circ. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1536\/ihj.14-335","article-title":"Clinical significance of high-sensitivity cardiac troponin T in patients with dilated cardiomyopathy","volume":"56","author":"Baba","year":"2015","journal-title":"Int. Heart J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/hrt.2004.043067","article-title":"Heart-type fatty acid binding protein is a novel prognostic marker in patients with non-ischaemic dilated cardiomyopathy","volume":"92","author":"Komamura","year":"2006","journal-title":"Heart"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cardfail.2006.10.014","article-title":"Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients","volume":"13","author":"Niizeki","year":"2007","journal-title":"J. Card. Fail."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cardfail.2004.03.005","article-title":"Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure","volume":"11","author":"Arimoto","year":"2005","journal-title":"J. Card. Fail."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4236\/wjcd.2018.89044","article-title":"Research progress of cardiac myosin binding protein C in dilated cardiomyopathy and other cardiac conditions","volume":"8","author":"Sun","year":"2018","journal-title":"World J. Cardiovas. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00395-010-0126-z","article-title":"Impact of troponin I-autoantibodies in chronic dilated and ischemic cardiomyopathy","volume":"106","author":"Doesch","year":"2011","journal-title":"Basic Res. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.111.243360","article-title":"Autoantibodies in heart failure and cardiac dysfunction","volume":"110","author":"Kaya","year":"2012","journal-title":"Circ. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1016\/j.ijcard.2013.08.005","article-title":"Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B+ tenascin-C and ED-A+ fibronectin in dilated cardiomyopathy: Potential impact on disease progression and patients\u2019 prognosis","volume":"168","author":"Franz","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s10517-018-4030-0","article-title":"Matrix metalloproteinases MMP-1 and MMP-9 and their inhibitor TIMP-1 as markers of dilated cardiomyopathy in patients of different age","volume":"164","author":"Antonov","year":"2018","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000368717","article-title":"Serum myeloperoxidase level is associated with heart-type fatty acid-binding protein but not troponin T in patients with chronic heart failure","volume":"24","author":"Gedikli","year":"2015","journal-title":"Med. Princ. Pract."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00395-008-0761-9","article-title":"Oxidative stress induces myeloperoxidase expression in endocardial endothelial cells from patients with chronic heart failure","volume":"104","author":"Eleuteri","year":"2009","journal-title":"Basic Res. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.amjcard.2006.04.018","article-title":"Plasma myeloperoxidase levels in patients with chronic heart failure","volume":"98","author":"Tang","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_64","first-page":"60","article-title":"Usefulness of serum myeloperoxidase in prediction of mortality in patients with severe heart failure","volume":"173","author":"Michowitz","year":"2008","journal-title":"Hypertension"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jacc.2007.02.053","article-title":"Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure","volume":"49","author":"Tang","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","article-title":"The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT","volume":"25","author":"Latini","year":"2004","journal-title":"Eur. Heart J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0735-1097(01)01672-2","article-title":"Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure","volume":"38","author":"Koglin","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjhyper.2006.06.016","article-title":"The G-231A polymorphism in the endothelin-A receptor gene is associated with lower aortic pressure in patients with dilated cardiomyopathy","volume":"20","author":"Telgmann","year":"2007","journal-title":"Am. J. Hypertens."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0735-1097(95)00520-X","article-title":"Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure","volume":"27","author":"Pacher","year":"1996","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1053\/euhj.2001.2626","article-title":"A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy","volume":"22","author":"Herrmann","year":"2001","journal-title":"Eur. Heart J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12265-015-9671-z","article-title":"Circulating endothelial progenitor cells: Potential biomarkers for idiopathic dilated cardiomyopathy","volume":"9","author":"Roura","year":"2016","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6487812","DOI":"10.1155\/2018\/6487812","article-title":"Stem cell therapy in patients with chronic nonischemic heart failure","volume":"2018","author":"Poglajen","year":"2018","journal-title":"Stem Cells Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s12265-013-9462-3","article-title":"New and emerging biomarkers in left ventricular systolic dysfunction\u2014insight into dilated cardiomyopathy","volume":"6","author":"Gopal","year":"2013","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/eurheartj\/ehm011","article-title":"Circulation of CD34+ progenitor cell populations in patients with idiopathic dilated and ischaemic cardiomyopathy (DCM and ICM)","volume":"28","author":"Theiss","year":"2007","journal-title":"Eur. Heart J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ejheart.2007.07.008","article-title":"Idiopathic dilated cardiomyopathy exhibits defective vascularization and vessel formation","volume":"9","author":"Roura","year":"2007","journal-title":"Eur. Heart J. Fail."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1161\/CIRCULATIONAHA.112.000230","article-title":"Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy","volume":"128","author":"Vrtovec","year":"2013","journal-title":"Circulation"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","article-title":"Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial","volume":"69","author":"Hare","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"137952","DOI":"10.1016\/j.scitotenv.2020.137952","article-title":"Cardiovascular toxicity and mechanism of bisphenol A and emerging risk of bisphenol S","volume":"723","author":"Zhang","year":"2020","journal-title":"Sci. Total Environ."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"133861","DOI":"10.1016\/j.scitotenv.2019.133861","article-title":"Bisphenol A in infant urine and baby-food samples among 9-to 15-month-olds","volume":"697","author":"Lee","year":"2019","journal-title":"Sci. Total Environ."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.scitotenv.2019.03.024","article-title":"Biomonitoring of bisphenols A, F, S in human milk and probabilistic risk assessment for breastfed infants","volume":"668","author":"Dualde","year":"2019","journal-title":"Sci. Total Environ."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"8399","DOI":"10.3390\/ijerph110808399","article-title":"Impact of bisphenol A on the cardiovascular system\u2014Epidemiological and experimental evidence and molecular mechanisms","volume":"11","author":"Gao","year":"2014","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.envint.2013.12.007","article-title":"Bisphenol A and human chronic diseases: Current evidences, possible mechanisms, and future perspectives","volume":"64","author":"Rezg","year":"2014","journal-title":"Environ. Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1021\/es9028292","article-title":"Urinary bisphenol A concentrations in relation to serum thyroid and reproductive hormone levels in men from an infertility clinic","volume":"44","author":"Meeker","year":"2010","journal-title":"Environ. Sci. Technol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.fertnstert.2013.04.017","article-title":"Serum bisphenol-A concentration and sex hormone levels in men","volume":"100","author":"Zhou","year":"2013","journal-title":"Fertil. Steril."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.3390\/ijerph120505329","article-title":"Elevated serum Bisphenol A level in patients with dilated cardiomyopathy","volume":"12","author":"Xiong","year":"2015","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_86","first-page":"1381","article-title":"Sex hormone-binding globulin: A new marker of disease severity and prognosis in men with chronic heart failure","volume":"62","author":"Tornel","year":"2019","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1002\/ehf2.13124","article-title":"Heart failure in the last year: Progress and perspective","volume":"7","author":"Tomasoni","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ejhf.1119","article-title":"Transcoronary concentration gradients of circulating microRNAs in heart failure","volume":"20","author":"Eposito","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_89","first-page":"S1885-5857(20)30398-4","article-title":"Ischemic dilated cardiomyopathy pathophysiology through microRNA-16-5p","volume":"10","author":"Mangas","year":"2019","journal-title":"Rev. Esp. Cardiol. Engl. Ed."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"BSR20180934","DOI":"10.1042\/BSR20180934","article-title":"Differential expression of circulating miRNAs as a novel tool to assess BAG3-associated familial dilated cardiomyopathy","volume":"39","author":"Zaragoza","year":"2019","journal-title":"BioSci. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2020.01.003","article-title":"Peripheral microRNA panels to guide the diagnosis of familial cardiomyopathy","volume":"218","author":"Belmonte","year":"2020","journal-title":"Transl. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cca.2018.12.022","article-title":"Syndecan-1 as an independent risk factor for the incidence of adverse cardiovascular events in patients having stage C and D heart failure with non-ischemic dilated cardiomyopathy","volume":"490","author":"Liu","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1253\/circj.CJ-14-1195","article-title":"Syndecan-1 in acute decompensated heart failure\u2013association with renal function and mortality","volume":"79","author":"Neves","year":"2015","journal-title":"Circ. J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1161\/CIRCHEARTFAILURE.113.000846","article-title":"Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction","volume":"7","author":"Tromp","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ejhf.1632","article-title":"Concentric vs. Eccentric remodelling in heart failure with reduced ejection fraction: Clinical characteristics, pathophysiology and response to treatment","volume":"22","author":"Nauta","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Baltr\u016bnien\u0117, V., Rink\u016bnait\u0117, I., Bogomolovas, J., Bironait\u0117, D., Ka\u017eukauskien\u0117, I., \u0160imoli\u016bnas, E., Ru\u010dinskas, K., Puronait\u0117, R., Bukelskien\u0117, V., and Grabauskien\u0117, V. (2020). The role of cardiac T-cadherin in the indicating heart failure severity of patients with non-ischemic dilated cardiomyopathy. Medicina, 56.","DOI":"10.3390\/medicina56010027"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/eurjhf\/hfs120","article-title":"Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support","volume":"14","author":"Lok","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1849454417751735","DOI":"10.1177\/1849454417751735","article-title":"Correlations of GDF-15 with sST2, MMPs, and worsening functional capacity in idiopathic dilated cardiomyopathy: Can we gain new insights into the pathophysiology?","volume":"7","author":"Nair","year":"2018","journal-title":"J. Circ. Biomark."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/jcmm.13540","article-title":"GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2","volume":"22","author":"Stojkovic","year":"2018","journal-title":"J. Cell Mol. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5688\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:08:31Z","timestamp":1760162911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":99,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["ijms22115688"],"URL":"https:\/\/doi.org\/10.3390\/ijms22115688","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]}}}